



## Lumos Pharma to Participate in Upcoming Investor Conferences

March 10, 2022

AUSTIN, Texas, March 10, 2022 (GLOBE NEWSWIRE) -- [Lumos Pharma, Inc.](#) (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will participate in the 34<sup>th</sup> Annual Roth Conference and the Maxim 2022 Virtual Growth Conference in March.

Event: **34<sup>th</sup> Annual Roth Conference – March 13-15**

Presentation: Live fireside chat March 14<sup>th</sup> at 10:30 AM PDT / 1:30 PM EDT

Webcast link: [Here](#)

Event: **Maxim 2022 Virtual Growth Conference – March 28-30**

Presentation: Pre-recorded presentation available beginning March 28<sup>th</sup> at 9:00 AM (EDT)

Webcast link: [Here](#) on the M-Vest conference platform

The webcasts for each presentation can also be found on the Company's website under "[Events & Presentations](#)" in the Investors & Media section where a replay of each presentation will also be available. Please contact your Roth or Maxim salesperson, or Lumos Pharma Investor Relations, to schedule one-on-one meetings with the management team during the conferences or thereafter.

### About Lumos Pharma

Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding from leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma's lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently being evaluated in a Phase 2 clinical trial, the OraGrowthH210 Trial, and a PK/PD trial, the OraGrowthH212 Trial, for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to recombinant growth hormone injections that PGHD patients otherwise endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit <https://lumos-pharma.com/>.

Investor & Media Contact:

Lisa Miller  
Lumos Pharma Investor Relations  
512-792-5454  
[ir@lumos-pharma.com](mailto:ir@lumos-pharma.com)

Source: Lumos Pharma, Inc.



Source: Lumos Pharma, Inc.